Hobson's Choice: Platelet Inhibition and Thrombocytopenia

Affiliations

¹ From the Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute of Primary Care and Health Sciences, Keele University, United Kingdom (M.A.M.); Academic Department of Cardiology, Royal Stoke Hospital, Stoke-on-Trent, United Kingdom (M.A.M.); and Department of Cardiology, University Hospital Southampton, University of Southampton, United Kingdom (N.C.). mamasmamas1@yahoo.co.uk.
² From the Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute of Primary Care and Health Sciences, Keele University, United Kingdom (M.A.M.); Academic Department of Cardiology, Royal Stoke Hospital, Stoke-on-Trent, United Kingdom (M.A.M.); and Department of Cardiology, University Hospital Southampton, University of Southampton, United Kingdom (N.C.).

Editorial

Mamas A Mamas et al. Circ Cardiovasc Interv. 2018 Apr.

. 2018 Apr;11(4):e006577.

doi: 10.1161/CIRCINTERVENTIONS.118.006577.

¹ From the Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute of Primary Care and Health Sciences, Keele University, United Kingdom (M.A.M.); Academic Department of Cardiology, Royal Stoke Hospital, Stoke-on-Trent, United Kingdom (M.A.M.); and Department of Cardiology, University Hospital Southampton, University of Southampton, United Kingdom (N.C.). mamasmamas1@yahoo.co.uk.
² From the Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute of Primary Care and Health Sciences, Keele University, United Kingdom (M.A.M.); Academic Department of Cardiology, Royal Stoke Hospital, Stoke-on-Trent, United Kingdom (M.A.M.); and Department of Cardiology, University Hospital Southampton, University of Southampton, United Kingdom (N.C.).

No abstract available

Keywords: Editorials; blood platelets; humans; percutaneous coronary intervention; thrombocytopenia.

Comment on

Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).
Groves EM, Bhatt DL, Steg PG, Deliargyris EN, Stone GW, Gibson CM, Hamm CW, Mahaffey KW, White HD, Angiolillo DJ, Prats J, Harrington RA, Price MJ. Groves EM, et al. Circ Cardiovasc Interv. 2018 Apr;11(4):e005635. doi: 10.1161/CIRCINTERVENTIONS.117.005635. Circ Cardiovasc Interv. 2018. PMID: 29632238